insulin glargine solostar

Generic: insulin glargine

Labeler: winthrop u.s.
NDC Directory HUMAN PRESCRIPTION DRUG BLA Inactive Finished

Drug Facts

Product Profile

Brand Name insulin glargine solostar
Generic Name insulin glargine
Labeler winthrop u.s.
Dosage Form INJECTION, SOLUTION
Routes
SUBCUTANEOUS
Active Ingredients

insulin glargine 100 [iU]/mL

Manufacturer
Winthrop U.S.

Identifiers & Regulatory

Product NDC 0955-1728
Product ID 0955-1728_81a7552c-6a2e-4c54-9bf7-56e15f7d166d
Product Type HUMAN PRESCRIPTION DRUG
Marketing Category BLA
Application Number BLA021081
Marketing Start 2022-05-02
Marketing End 2026-03-31

Pharmacologic Class

Established (EPC)
insulin analog [epc]
Chemical Structure
insulin [cs]

Normalized Code Variants

Searchable formats for this product NDC code

Digits Only 09551728
Hyphenated Format 0955-1728

Supplemental Identifiers

RxCUI
311041 847230
UNII
2ZM8CX04RZ
NUI
M0011417 N0000175453

Packaging Origin

Original Packager
true

Resolved Product View

Precedence rule: structured NDC data is preferred, falling back to linked label metadata when unavailable. Source tags show the origin of each value.

Resolved Identity

Brand Name insulin glargine solostar (source: ndc)
Generic Name insulin glargine (source: ndc)
Application Number BLA021081 (source: ndc)
Routes
SUBCUTANEOUS
source: ndc

Resolved Composition

Strengths
  • 100 [iU]/mL
source: ndc
Packaging
  • 16 HOW SUPPLIED/STORAGE AND HANDLING 16.1 How Supplied Insulin Glargine injection is supplied as a clear and colorless solution containing 100 units/mL (U-100) available as follows: Insulin Glargine NDC number Package size 10 mL Multiple-dose vial 0955-1729-01 1 vial per carton 3 mL SoloStar single-patient-use prefilled pen 0955-1728-05 5 pens per carton Additional Information about Insulin Glargine Solostar: The Insulin Glargine SoloStar prefilled pen dials in 1-unit increments. Needles are not included in the packs. Use BD Ultra-Fine ® needles Other brands listed are the trademarks of their respective owners and are not trademarks of sanofi-aventis U.S. LLC with the SoloStar prefilled pens (these BD manufactured needles are sold separately). 16.2 Storage Dispense in the original sealed carton with the enclosed Instructions for Use. Store unused Insulin Glargine in a refrigerator between 36°F and 46°F (2°C and 8°C). Do not freeze. Discard Insulin Glargine if it has been frozen. Protect Insulin Glargine from direct heat and light. Storage conditions are summarized in the following table. Not in-use (unopened) Not in-use (unopened) In-use (opened) Refrigerated Room Temperature (36°F–46°F [2°C–8°C]) (up to 86°F [30°C]) (see temperature below) 10 mL multiple-dose vial Until expiration date 28 days 28 days Refrigerated or room temperature 3 mL single-patient-use SoloStar prefilled pen Until expiration date 28 days 28 days Room temperature only (Do not refrigerate)
  • PRINCIPAL DISPLAY PANEL - One 10 mL Vial Carton NDC 0955-1729-01 Rx only Winthrop A SANOFI COMPANY Insulin glargine injection 100 units/mL (U-100) For subcutaneous injection only Do not mix with other insulins Use only if solution is clear and colorless with no particles visible Use with U-100 syringe only One 10 mL multiple-dose vial SANOFI PRINCIPAL DISPLAY PANEL - One 10 mL Vial Carton
  • PRINCIPAL DISPLAY PANEL - Five 3 mL Pen Carton Winthrop A SANOFI COMPANY NDC 0955-1728-05 Insulin glargine injection SoloStar ® For Single Patient Use Only Five 3 mL Prefilled Pens – Dispense in this sealed carton Solution for injection in a disposable insulin delivery device Do not mix with other insulins For subcutaneous injection only Use only if solution is clear and colorless with no particles visible Use within 28 days after initial use *Needles not included (see back panel) Rx ONLY 100 units/mL (U-100) SANOFI PRINCIPAL DISPLAY PANEL - Five 3 mL Pen Carton
source: label

Packages (0)

No package records.

Ingredients (1)

insulin glargine (100 [iU]/mL)

Linked Drug Pages (1)

Raw FDA Data

View complete raw FDA NDC JSON payload
{"route": ["SUBCUTANEOUS"], "spl_id": "81a7552c-6a2e-4c54-9bf7-56e15f7d166d", "openfda": {"nui": ["M0011417", "N0000175453"], "unii": ["2ZM8CX04RZ"], "rxcui": ["311041", "847230"], "spl_set_id": ["406883ea-7f97-4eff-8d43-0bab004654f1"], "pharm_class_cs": ["Insulin [CS]"], "pharm_class_epc": ["Insulin Analog [EPC]"], "manufacturer_name": ["Winthrop U.S."], "is_original_packager": [true]}, "finished": true, "packaging": [], "brand_name": "Insulin Glargine Solostar", "product_id": "0955-1728_81a7552c-6a2e-4c54-9bf7-56e15f7d166d", "dosage_form": "INJECTION, SOLUTION", "pharm_class": ["Insulin Analog [EPC]", "Insulin [CS]"], "product_ndc": "0955-1728", "generic_name": "insulin glargine", "labeler_name": "Winthrop U.S.", "product_type": "HUMAN PRESCRIPTION DRUG", "brand_name_base": "Insulin Glargine Solostar", "active_ingredients": [{"name": "INSULIN GLARGINE", "strength": "100 [iU]/mL"}], "application_number": "BLA021081", "marketing_category": "BLA", "marketing_end_date": "20260331", "marketing_start_date": "20220502"}